
Elucent Medical, Inc. Risk Report
Explore Elucent Medical, Inc. across six non‑financial risk dimensions:ESG, Workforce, News & Media, Cybersecurity, Legal & Regulatory, Operational. Unlock the full report, original sources and timelines, and enable continuous monitoring.
Summary
📜 Innovation & R&D
Elucent Medical, Inc. is actively engaged in multiple innovative projects aimed at enhancing medical procedures related to breast cancer localization and surgery. The company has been recognized for their advancements in creating technology that may transform oncologic surgery practices. Their efforts in research and development are evident through their successful funding rounds and introduction of new technologies.
- Elucent Medical received FDA breakthrough device status for its surgical navigation system on 🗓 May 15, 2025, marking a significant milestone in their innovation efforts.
- The company secured Series C funding on 🗓 April 10, 2024, to propel their technological advancements in oncologic surgery.
- They raised $42.5 million on 🗓 April 16, 2024, specifically to develop cancer-surgery navigation technology.
- UW–Madison professors, in collaboration with the company, created a revolutionary GPS device for surgeons, highlighted on 🗓 January 20, 2020.
Profile
News & Media
Real‑time aggregation of trusted sources tracking company‑related events with sentiment and topic tags for rapid risk triage.
Sign up to unlock Elucent Medical, Inc.’s complete news feed with sentiment and topic tags.
View Full ReportEntity List
Continuous third‑party screening across global sanctions, enforcement, and watchlist sources with unified entity resolution and real‑time alerts.
Name | Issuer | Status |
---|---|---|
ACF List of War Enablers | Anti-Corruption Foundation | |
African Development Bank Debarred Entities | African Development Bank Group | |
Argentina Members of Parliament | Honorable Cámara de Diputados de la Nación Argentina | |
Argentina RePET Sanctions | Ministerio de Justicia | |
Armenia Public Officials and Associates | Hetq Online | |
Asian Development Bank Sanctions | Asian Development Bank | |
Australian Sanctions Consolidated List | Department of Foreign Affairs and Trade | |
Democratic People's Republic Of Korea (North Korea) Sanctions Regime | Department of Foreign Affairs and Trade | |
Former Federal Republic Of Yugoslavia Sanctions Regime | Department of Foreign Affairs and Trade | |
Iran Sanctions Regime | Department of Foreign Affairs and Trade |
Sign up to unlock Elucent Medical, Inc.’s sanctions, enforcement, and watchlist risk profile.
View Full ReportESG
Verification of declared ESG commitments and certifications with evidence links, score signals, and status updates across E, S, and G.
Name | Status |
---|---|
Sustainable Finance Disclosure Regulation | |
Global Reporting Initiative Standards | |
EU Taxonomy Regulation | |
EU Corporate Sustainability Reporting Directive | |
California Transparency in Supply Chains Act | |
EU Non-Financial Reporting Directive | |
ISO 14001 | |
Sustainability Accounting Standards Board Standards | |
Task Force on Climate-related Financial Disclosures | |
UN Guiding Principles on Business and Human Rights |
Sign up to unlock Elucent Medical, Inc.’s ESG commitments, certifications, and controversy signals.
View Full ReportCybersecurity
Verification of adherence to recognized security standards, mapping control coverage and gaps affecting third‑party and supply‑chain risk.
Certification | Status |
---|---|
General Data Protection Regulation | |
Digital Operational Resilience Act | |
Cybersecurity Maturity Model Certification | |
NIST Cybersecurity Framework | |
NIST 800-53 Revision 5 | |
California Consumer Privacy Act | |
ISO/IEC 27001 | |
Health Insurance Portability and Accountability Act | |
Payment Card Industry Data Security Standard | |
Federal Information Security Modernization Act |
Sign up to unlock Elucent Medical, Inc.’s security standards, control gaps, and exposure risks.
View Full ReportGet Elucent Medical, Inc.'s full Non-Financial Risk Report
By signing up, you agree to our Terms and Privacy Policy.